Evaluation of linagliptin dissolution from tablets using HPLC and UV methods

Rita Elena de Abreu Engel; Amanda Thomas Barden; Sarah Chagas Campanharo; Natália Olegário; Nadia Maria Volpato; Elfrides Eva Scherman Schapoval

doi:10.22456/2527-2616.97847

Authors

Rita Elena de Abreu Engel Faculty of Pharmacy - Federal University of Rio Grande do Sul
Amanda Thomas Barden Faculty of Pharmacy - Federal University of Rio Grande do Sul
Sarah Chagas Campanharo Faculty of Pharmacy - Federal University of Rio Grande do Sul
Natália Olegário Faculty of Pharmacy - Federal University of Rio Grande do Sul
Nadia Maria Volpato Faculty of Pharmacy - Federal University of Rio Grande do Sul
Elfrides Eva Scherman Schapoval Faculty of Pharmacy - Federal University of Rio Grande do Sul

DOI:

https://doi.org/10.22456/2527-2616.97847

Keywords:

Linagliptin, Dissolution test, UV spectrophotometric method, HPLC method, Biowaiver, Quality control

Abstract

Linagliptin (LGT) is used to reduce glucose blood levels in patients with type 2 Diabetes mellitus. The proposed conditions for a biowaiver guide can be applied due to high solubility of linagliptin in aqueous media. The aim of the present study was to develop and validate a dissolution test for 5 mg linagliptin coated tablets. After diverse dissolution procedure evaluation, the selected method was achieved using USP apparatus 1 (basket) at 75 rpm and 900 mL of citrate buffer pH 3.5 as dissolution medium. The conditions proposed by biowaiver guide were also applied to this drug, using USP apparatus 2 (paddle) and 900 mL of 0.1 M HCl, pH 4.5 acetate buffer and pH 6.8 phosphate buffer as dissolution medium. HPLC and UV spectrophotometry were used to LGT quantitation and validated for this purpose. The chromatographic and spectrophotometric methods in the dissolution context proved to be linear in 0.5 – 20.0 μg.mL^-1 range, precise with RSD values less than 1.0 % and 2.0%, respectively, and accurate (mean recovery 100.29 % and 100.59%). The parameters such as specificity, linearity, accuracy, precision and robustness were according to international guidelines for both methods HPLC and UV. Dissolved linagliptin results were compared using the Student’s t-test and the data found were not significant different (P=0.068). In most dissolution conditions evaluated, LGT presented more than 85% drug dissolved from the tablets in fifteen minutes. The proposed methods can be applied for quality control of this gliptin. According to the results, linagliptin may be a biowaiver candidate.

Downloads

Download data is not yet available.

References

IDF. International Diabetes Federation.The IDF Diabetes Atlas. Fifth Edition. Brussels, 2011.

Scheen A J. DPP-4 innibitors in the management of type 2 diabetes: A critical review of head-to-head trials. Diabetes Metab 2012; 38:89-101.

Food and Drug Administration. Highlights of prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/20 12/201280s005lbl.pdf>. Accessed on 23 October 2019.

Marques M, Brown W. Desenvolvimento e validação de métodos de dissolução para formas farmacêuticas sólidas orais. Analytica 2002; 1:48-51.

Storpirtis S S; Gonçalves J E, Chiann C, Gai M N. Biofarmacotécnica. Rio de Janeiro: Guanabara Koogan, 2009:95-96.

FDA. Food and Drugs Administration. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, 2017. Available at: https://www.fda.gov/media/70963/download Accessed on 23 October 2019.

Tradjenta (linagliptin). Ridgefield, Conn: Boehringer Ingelheim Pharmaceuticals, Inc; 2011.

TGA. Therapeutical Goods Administration. Australian Public Assessment Report for Linagliptin, 2011. Available at: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.ns f/pdf?OpenAgent&id=CP-2011-PI-03485- 3&d=2016042616114622483. Accessed on 26 April 2016.

EMEA. European Medicines Agency. Guideline on the investigation of bioequivalence, 2009. Available at: http://www.ema.europa.eu/docs/en_GB/document_librar y/Scientific_guideline/2009/09/WC500003011.pdf. Accessed on 26 April 2016.

Brasil. Resolução da Diretoria Colegiada RDC Nº 37, de 3 de agosto de 2011. Guia para isenção e substituição de estudos de biodisponibilidade relativa/bioequivalência e dá outras providências. Diário Oficial da União, Brasília, 2011. Available at: http://portal.anvisa.gov.br/wps/wcm/connect/1c626d004 0cb51e6952eb51b0133649b/rdc0037_03_08_2011.pdf? MOD=AJPERES. Accessed on 26 April 2016.

Barden AT, Engel, REA, Campanharo S, Volpato NM, Schapoval, EES. Characterization of linagliptin using analytical techniques. Drug Anal Res, 2017; 01: 30-37. Hanson, W A. Handbook of dissolution testing. 2. ed. Oregon: Aster Publishing Corporation, 1991:159.

Lange A D C, Batistel A P, Sfair L L, Carlosso J, Volpato N M, Schapoval E E S. Sitagliptin Phosphate: Development of a Dissolution Method for Coated Tablets Based on In Vivo Data for Improving Medium Sensitivity. Dissolution Technol 2014; 21:17-22.

Barden A T. Dissertação de mestrado. Desenvolvimento e validação de métodos analíticos para determinação de Vildagliptina em comprimidos. Universidade Federal do Rio Grande do Sul, Porto Alegre, 2010.

WHO. World Health Organization. About diabetes. Available at: http://www.who.int/diabetes/action_online/basics/en/. Accessed on 26 April 2016.

ICH. Harmonised Tripartite Guideline. Validation of Analytical methods text and methodology Q2(R1). In: Internacional Conference on Harmonization of Technical Requirenments for Registration of Pharmaceuticals for Human Use, 2005.

Brasil. Resolução RDC nº 166, de 24 de julho de 2017. Dispõe sobre a validação de métodos analíticos e dá outras providências. Diário Oficial da União, Brasília, 2017. Available at: http://portal.anvisa.gov.br/documents/10181/2721567/R DC_166_2017_COMP.pdf/d5fb92b3-6c6b-4130-8670- 4e3263763401. Accessed on 23 October 2019.